NATICK, Mass., May 15, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces results from the REPRISE I feasibility trial, which evaluated the acute safety of the Lotus(TM)

Patients with mitral regurgitation, a type of valvular heart disease common in the elderly, are living longer after surgery.

BETHLEHEM, Pa., May 9, 2012 /PRNewswire/ -- Micro Interventional Devices, Inc.(TM) (MID), an emerging cardiovascular medical

NATICK, Mass., April 23, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate

Patients with rheumatic heart disease (RHD) are being admitted to hospital too late to prevent the need for heart surgery.